REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS 2021 2020 Reported Operational (1) Currency 2021 2020 Reported Operational (1) Currency CONSUMER HEALTH SEGMENT (2) OTC US 675 $ 627 7.7% 7.7% - 1,274 $ 1,316 -3.2% -3.2% - Intl 633 522 21.2% 10.4% 10.8% 1,208 1,181 2.3% -4.7% 7.0% WW 1,307 1,149 13.8% 8.9% 4.9% 2,482 2,497 -0.6% -3.9% 3.3% SKIN HEALTH / BEAUTY US 659 536 23.0% 23.0% - 1,293 1,195 8.2% 8.2% - Intl 511 471 8.4% 1.4% 7.0% 1,040 929 12.0% 6.8% 5.2% WW 1,170 1,007 16.2% 12.9% 3.3% 2,333 2,124 9.8% 7.6% 2.2% ORAL CARE US 165 170 -3.1% -3.1% - 328 346 -5.2% -5.2% - Intl 260 227 14.6% 6.7% 7.9% 514 446 15.3% 10.2% 5.1% WW 426 397 7.0% 2.5% 4.5% 843 792 6.3% 3.5% 2.8% BABY CARE US 97 96 0.8% 0.8% - 193 188 2.4% 2.4% - Intl 290 260 11.5% 6.6% 4.9% 583 529 10.2% 9.0% 1.2% WW 387 356 8.6% 5.0% 3.6% 776 717 8.1% 7.3% 0.8% WOMEN'S HEALTH US 3 3 -3.1% -3.1% - 6 7 -16.0% -16.0% - Intl 227 199 14.2% 9.2% 5.0% 446 427 4.5% 3.1% 1.4% WW 230 202 13.9% 9.0% 4.9% 452 434 4.2% 2.8% 1.4% WOUND CARE / OTHER US 153 126 20.9% 20.9% - 268 245 9.3% 9.3% - Intl 64 59 7.3% -2.8% 10.1% 125 111 12.1% 5.2% 6.9% WW 216 185 16.6% 13.4% 3.2% 393 356 10.2% 8.0% 2.2% TOTAL CONSUMER HEALTH US 1,751 1,557 12.4% 12.4% - 3,362 3,297 2.0% 2.0% - Intl 1,984 1,739 14.1% 6.3% 7.8% 3,916 3,624 8.1% 3.3% 4.8% WW 3,735 $ 3,296 13.3% 9.2% 4.1% 7,278 $ 6,921 5.2% 2.7% 2.5% See footnotes at end of schedule % Change % Change -- 1 of 6 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS PHARMACEUTICAL SEGMENT (2,3) 2021 2020 Reported Operational (1) Currency 2021 2020 Reported Operational (1) Currency IMMUNOLOGY US 2,748 $ 2,362 16.4% 16.4% - 5,161 $ 4,772 8.2% 8.2% - Intl 1,483 1,161 27.7% 18.2% 9.5% 2,984 2,389 24.9% 17.0% 7.9% WW 4,231 3,523 20.1% 17.0% 3.1% 8,145 7,161 13.7% 11.1% 2.6% REMICADE US 540 593 -9.1% -9.1% - 1,029 1,218 -15.6% -15.6% - US Exports (4) 93 133 -30.0% -30.0% - 150 243 -38.2% -38.2% - Intl 255 208 22.4% 11.1% 11.3% 487 464 4.9% -1.7% 6.6% WW 888 935 -5.1% -7.6% 2.5% 1,665 1,925 -13.5% -15.1% 1.6% SIMPONI / SIMPONI ARIA US 290 256 12.8% 12.8% - 545 528 3.2% 3.2% - Intl 294 289 1.7% -3.8% 5.5% 601 547 9.8% 4.5% 5.3% WW 584 546 6.9% 4.0% 2.9% 1,146 1,075 6.6% 3.8% 2.8% STELARA US 1,496 1,138 31.4% 31.4% - 2,827 2,355 20.0% 20.0% - Intl 778 558 39.2% 28.6% 10.6% 1,595 1,161 37.3% 28.1% 9.2% WW 2,274 1,697 34.0% 30.5% 3.5% 4,422 3,516 25.8% 22.7% 3.1% TREMFYA US 325 241 35.0% 35.0% - 599 428 40.0% 40.0% - Intl 155 101 52.3% 41.1% 11.2% 298 210 41.8% 31.8% 10.0% WW 479 342 40.2% 36.8% 3.4% 897 638 40.6% 37.3% 3.3% OTHER IMMUNOLOGY US 5 - * * - 12 - * * - Intl 1 3 -61.3% -67.9% 6.6% 3 6 -51.2% -53.9% 2.7% WW 7 3 * * * 15 6 * * * INFECTIOUS DISEASES US 444 416 6.8% 6.8% - 956 852 12.2% 12.2% - Intl 585 463 26.3% 18.2% 8.1% 1,079 946 14.1% 7.8% 6.3% WW 1,028 878 17.1% 12.8% 4.3% 2,035 1,798 13.2% 9.9% 3.3% COVID-19 VACCINE US 51 - * * - 151 - * * - Intl 113 - * * - 113 - * * - WW 164 - * * - 264 - * * - EDURANT / rilpivirine US 9 10 -9.3% -9.3% - 19 22 -10.9% -10.9% - Intl 253 246 2.8% -4.0% 6.8% 486 458 6.0% -1.7% 7.7% WW 262 256 2.3% -4.2% 6.5% 505 480 5.2% -2.1% 7.3% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 368 379 -3.2% -3.2% - 748 775 -3.5% -3.5% - Intl 137 130 5.5% -5.9% 11.4% 303 314 -3.5% -8.5% 5.0% WW 505 510 -1.0% -3.9% 2.9% 1,051 1,089 -3.5% -5.0% 1.5% OTHER INFECTIOUS DISEASES US 16 25 -36.2% -36.2% - 37 54 -31.3% -31.3% - Intl 81 87 -6.2% -13.4% 7.2% 177 174 1.8% -3.0% 4.8% WW 98 113 -13.0% -18.5% 5.5% 215 229 -6.1% -9.7% 3.6% % Change % Change -- 2 of 6 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS 2021 2020 Reported Operational (1) Currency 2021 2020 Reported Operational (1) Currency NEUROSCIENCE US 842 778 8.0% 8.0% - 1,613 1,526 5.6% 5.6% - Intl 967 809 19.6% 13.1% 6.5% 1,916 1,719 11.5% 6.3% 5.2% WW 1,808 1,587 13.9% 10.6% 3.3% 3,529 3,245 8.7% 6.0% 2.7% CONCERTA / Methylphenidate US 35 55 -36.0% -36.0% - 82 107 -23.1% -23.1% - Intl 127 94 33.7% 25.6% 8.1% 250 212 17.5% 11.1% 6.4% WW 161 149 8.1% 3.0% 5.1% 332 320 3.9% -0.3% 4.2% INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 645 576 11.9% 11.9% - 1,234 1,120 10.2% 10.2% - Intl 380 303 25.1% 15.9% 9.2% 756 642 17.7% 9.9% 7.8% WW 1,024 879 16.4% 13.3% 3.1% 1,989 1,762 12.9% 10.1% 2.8% RISPERDAL CONSTA US 72 74 -3.0% -3.0% - 139 150 -7.5% -7.5% - Intl 84 79 6.4% 0.2% 6.2% 173 173 0.4% -4.6% 5.0% WW 155 153 1.9% -1.3% 3.2% 312 323 -3.3% -6.0% 2.7% OTHER NEUROSCIENCE US 91 75 20.9% 20.9% - 158 150 5.6% 5.6% - Intl 377 331 13.8% 10.0% 3.8% 738 691 6.7% 4.3% 2.4% WW 468 406 15.1% 12.0% 3.1% 896 841 6.5% 4.5% 2.0% ONCOLOGY US 1,462 1,181 23.7% 23.7% - 2,839 2,356 20.5% 20.5% - Intl 2,073 1,609 28.8% 19.8% 9.0% 4,266 3,448 23.7% 16.2% 7.5% WW 3,535 2,791 26.7% 21.5% 5.2% 7,105 5,804 22.4% 17.9% 4.5% DARZALEX US 770 492 56.7% 56.7% - 1,461 955 53.1% 53.1% - Intl 663 409 62.1% 50.3% 11.8% 1,337 883 51.4% 42.3% 9.1% WW 1,433 901 59.2% 53.8% 5.4% 2,798 1,838 52.2% 47.9% 4.3% ERLEADA US 193 136 41.5% 41.5% - 364 255 42.7% 42.7% - Intl 109 33 * * * 199 57 * * * WW 302 170 77.6% 73.7% 3.9% 563 313 80.0% 76.4% 3.6% IMBRUVICA US 454 447 1.7% 1.7% - 898 879 2.2% 2.2% - Intl 662 502 31.9% 22.1% 9.8% 1,342 1,101 21.9% 14.2% 7.7% WW 1,116 949 17.7% 12.5% 5.2% 2,241 1,980 13.2% 8.9% 4.3% ZYTIGA / abiraterone acetate US 21 87 -75.3% -75.3% - 71 226 -68.5% -68.5% - Intl 542 480 12.8% 5.4% 7.4% 1,130 1,032 9.5% 2.5% 7.0% WW 563 568 -0.8% -7.1% 6.3% 1,201 1,258 -4.5% -10.3% 5.8% OTHER ONCOLOGY US 23 20 18.8% 18.8% - 44 42 6.3% 6.3% - Intl 97 185 -47.2% -49.6% 2.4% 258 375 -31.0% -34.3% 3.3% WW 120 204 -40.9% -43.0% 2.1% 302 416 -27.3% -30.2% 2.9% % Change % Change -- 3 of 6 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS 2021 2020 Reported Operational (1) Currency 2021 2020 Reported Operational (1) Currency PULMONARY HYPERTENSION US 595 545 9.0% 9.0% - 1,168 1,031 13.2% 13.2% - Intl 275 243 13.5% 7.9% 5.6% 563 503 12.1% 6.7% 5.4% WW 870 789 10.4% 8.7% 1.7% 1,731 1,534 12.9% 11.1% 1.8% OPSUMIT US 290 256 13.6% 13.6% - 562 485 15.9% 15.9% - Intl 172 150 14.9% 9.0% 5.9% 351 310 13.1% 7.6% 5.5% WW 463 406 14.1% 11.9% 2.2% 913 795 14.8% 12.7% 2.1% UPTRAVI US 268 254 6.0% 6.0% - 527 466 13.3% 13.3% - Intl 45 28 54.9% 42.9% 12.0% 91 66 36.8% 27.4% 9.4% WW 313 282 11.0% 9.8% 1.2% 618 532 16.2% 15.0% 1.2% OTHER PULMONARY HYPERTENSION US 36 37 -2.4% -2.4% - 78 81 -3.0% -3.0% - Intl 59 64 -8.2% -10.3% 2.1% 122 126 -3.5% -6.3% 2.8% WW 95 101 -6.1% -7.5% 1.4% 200 207 -3.3% -5.0% 1.7% CARDIOVASCULAR / METABOLISM / OTHER US 780 837 -6.9% -6.9% - 1,579 1,643 -3.9% -3.9% - Intl 346 347 -0.3% -8.4% 8.1% 674 701 -3.8% -9.9% 6.1% WW 1,126 1,184 -5.0% -7.3% 2.3% 2,253 2,344 -3.9% -5.7% 1.8% XARELTO US 569 559 1.8% 1.8% - 1,158 1,086 6.6% 6.6% - Intl - - - - - - - - - - WW 569 559 1.8% 1.8% - 1,158 1,086 6.6% 6.6% - INVOKANA / INVOKAMET US 96 132 -27.0% -27.0% - 183 249 -26.6% -26.6% - Intl 64 47 33.8% 22.1% 11.7% 127 105 20.3% 12.2% 8.1% WW 160 179 -10.9% -14.0% 3.1% 310 354 -12.6% -15.0% 2.4% PROCRIT / EPREX US 59 70 -16.3% -16.3% - 121 146 -17.3% -17.3% - Intl 69 66 3.7% -4.5% 8.2% 133 145 -8.2% -14.1% 5.9% WW 127 136 -6.6% -10.6% 4.0% 254 291 -12.8% -15.7% 2.9% OTHER US 57 78 -26.7% -26.7% - 117 163 -27.8% -27.8% - Intl 214 234 -8.4% -15.7% 7.3% 415 451 -8.1% -13.7% 5.6% WW 271 312 -13.0% -18.4% 5.4% 532 614 -13.3% -17.4% 4.1% TOTAL PHARMACEUTICAL US 6,869 6,120 12.2% 12.2% - 13,315 12,181 9.3% 9.3% - Intl 5,730 4,632 23.7% 15.4% 8.3% 11,483 9,705 18.3% 11.4% 6.9% WW 12,599 $ 10,752 17.2% 13.6% 3.6% 24,798 $ 21,886 13.3% 10.3% 3.0% See footnotes at end of schedule % Change % Change -- 4 of 6 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS MEDICAL DEVICES SEGMENT (2) 2021 2020 Reported Operational (1) Currency 2021 2020 Reported Operational (1) Currency INTERVENTIONAL SOLUTIONS US 475 $ 255 86.5% 86.5% - 909 620 46.7% 46.7% - Intl 572 335 70.5% 59.8% 10.7% 1,086 697 55.7% 46.4% 9.3% WW 1,046 590 77.4% 71.3% 6.1% 1,995 1,317 51.5% 46.5% 5.0% ORTHOPAEDICS US 1,323 869 52.3% 52.3% - 2,572 2,119 21.4% 21.4% - Intl 904 583 55.1% 43.2% 11.9% 1,768 1,371 29.0% 20.2% 8.8% WW 2,227 1,451 53.4% 48.6% 4.8% 4,340 3,489 24.4% 20.9% 3.5% HIPS US 234 137 70.5% 70.5% - 444 343 29.6% 29.6% - Intl 159 88 78.6% 64.3% 14.3% 305 220 38.3% 28.6% 9.7% WW 392 226 73.7% 68.1% 5.6% 749 563 33.0% 29.2% 3.8% KNEES US 210 108 94.3% 94.3% - 395 322 22.7% 22.7% - Intl 140 66 * 95.1% 16.8% 272 196 39.2% 29.5% 9.7% WW 350 174 * 94.6% 6.4% 667 517 28.9% 25.2% 3.7% TRAUMA US 447 354 26.0% 26.0% - 897 761 17.8% 17.8% - Intl 263 198 32.7% 22.7% 10.0% 545 445 22.5% 14.4% 8.1% WW 710 553 28.4% 24.8% 3.6% 1,443 1,207 19.6% 16.5% 3.1% SPINE, SPORTS & OTHER US 433 270 60.6% 60.6% - 836 693 20.7% 20.7% - Intl 343 230 49.0% 37.9% 11.1% 646 510 26.7% 18.0% 8.7% WW 776 499 55.3% 50.2% 5.1% 1,482 1,202 23.2% 19.6% 3.6% % Change % Change -- 5 of 6 -- REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM) SECOND QUARTER SIX MONTHS 2021 2020 Reported Operational (1) Currency 2021 2020 Reported Operational (1) Currency SURGERY US 1,035 490 * * - 1,933 1,334 44.9% 44.9% - Intl 1,487 1,060 40.2% 30.6% 9.6% 2,961 2,317 27.8% 20.4% 7.4% WW 2,522 1,551 62.6% 56.0% 6.6% 4,894 3,651 34.0% 29.3% 4.7% ADVANCED US 459 277 65.4% 65.4% - 864 658 31.3% 31.3% - Intl 708 498 42.2% 32.5% 9.7% 1,421 1,065 33.4% 25.6% 7.8% WW 1,168 775 50.5% 44.3% 6.2% 2,286 1,723 32.6% 27.8% 4.8% GENERAL US 576 213 * * - 1,069 676 58.1% 58.1% - Intl 779 562 38.5% 28.9% 9.6% 1,540 1,252 23.0% 15.9% 7.1% WW 1,354 775 74.7% 67.8% 6.9% 2,608 1,928 35.3% 30.7% 4.6% VISION US 467 248 88.3% 88.3% - 939 687 36.6% 36.6% - Intl 716 447 60.0% 53.7% 6.3% 1,389 1,075 29.2% 24.6% 4.6% WW 1,183 695 70.1% 66.0% 4.1% 2,328 1,762 32.1% 29.3% 2.8% CONTACT LENSES / OTHER US 352 203 73.3% 73.3% - 723 549 31.6% 31.6% - Intl 517 352 47.0% 41.9% 5.1% 1,003 819 22.5% 18.5% 4.0% WW 868 554 56.7% 53.4% 3.3% 1,725 1,368 26.1% 23.7% 2.4% SURGICAL US 115 45 * * - 216 138 56.3% 56.3% - Intl 199 96 * 97.1% 10.6% 386 256 50.9% 44.4% 6.5% WW 314 141 * * * 602 394 52.8% 48.6% 4.2% TOTAL MEDICAL DEVICES US 3,299 1,862 77.2% 77.2% - 6,353 4,760 33.5% 33.5% - Intl 3,679 2,426 51.6% 41.9% 9.7% 7,204 5,460 31.9% 24.5% 7.4% WW 6,978 $ 4,288 62.7% 57.2% 5.5% 13,557 $ 10,220 32.7% 28.7% 4.0% * Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency (2) Unaudited (3) Certain prior year amounts have been reclassified to conform to current year product disclosures (4) Reported as U.S. sales Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. % Change % Change -- 6 of 6 --